Integrated Diagnostics Holdings PLC

Director's Dealing • Mar 1, 2022

National Storage Mechanism | Additional information

RNS Number : 2260D

Integrated Diagnostics Holdings PLC

01 March 2022

Integrated Diagnostics Holdings PLC

1 March 2022

Integrated Diagnostic Holdings plc (the "Company")

Directorate Change

The Board announces the appointment of Ms Yvonne Stillhart, as a Non-Executive Director of the Company with effect from 1 March 2022.  Yvonne also joins the Audit and the Remuneration Committees.

Yvonne is a seasoned Senior Executive working with innovation and growth driven companies across a wide range of industries and geographical regions, including Europe, USA, North Africa and Sub-Sahara Africa. She has been a Non-Executive Director and Audit and Risk Committee Member for more than 12 years. She has co-founded and led as a Senior Partner a specialised private equity manager in Switzerland. For several decades Yvonne has been a senior executive leader in international businesses, private market and infrastructure investments. She is focussed on business building and transformation, risk management and ESG governance.

Yvonne serves currently as a non-executive Director of UBS Asset Management Switzerland Ltd. and is the Chairperson of the South African EPE Capital Ltd. She is also on the Board of Standard Life Private Equity Trust Plc.

Yvonne holds a Director Certificate from Harvard Business School, the Corporate Risk Certificate from the DCRO Institute and the ESG Competent Boards Certificate.

Yvonne replaces James Nolan who resigned on 1 September 2021.

There are no other details that are required to be disclosed under the Financial Conduct Authority LR 9.6.13 of the Listing Rules in relation to this appointment.

For further information please contact:

Integrated Diagnostic Holdings plc	+20(0)2 3345 5530
Nancy Fahmy Investor Relations Director
Company Secretary: Link Company Matters Limited	[email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAUPUBPWUPPGWG